Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). OBJECTIVE: To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. METHODS: In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer's disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. RESULTS: We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. CONCLUSION: Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, some studies reported elevated blood GFAP in participants with FTD compared to controls [8–18] but others observed no such GFAP increase in FTD [19–22].”
From Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, some investigators [8, 11, 14] but not others [9, 21–23] found that blood GFAP concentrations correlate with clinical markers of disease severity in participants with FTD.”
From Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders (2025) · cites this paper as [11]
In the citing paper
“In previous studies, NfL showed good discriminatory power, in CSF and serum, for the differentiation of FTD from controls (area under the curve (AUC) up to 0.88) [25, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Corticocortical inhibition in human motor cortex.
Kujirai, T., Caramia, M. D., Rothwell, J. C., Day, B. L., Thompson, P. D., Ferbert, A., Wroe, S., Asselman, P., & Marsden, C. D. (1993) · The Journal of Physiology · doi:10.1113/jphysiol.1993.sp019912 · Cited by 3,131 · cited 1×
“ForSICI and ICF, the conditioning stimulus (CS) was adjusted at 70% of the RMT, employing multiple interstimulus intervals (ISIs), including 1, 2, 3 ms for SICI and 7, 10, 15 ms for ICF [47, 48].”
Rossini, P. M., Burke, D., Chen, R., Cohen, L. G., Daskalakis, Z., Di Iorio, R., Di Lazzaro, V., Ferreri, F., Fitzgerald, P. B., George, M. S., et al. (2015) · Clinical Neurophysiology · doi:10.1016/j.clinph.2015.02.001 · Cited by 2,753
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · cited 1×
“Thecohortconsistedof282patientsmeetingprob-ableclinicalcriteriaforasyndromeintheFTLD spectrum,namely130bvFTD,48avPPA,24svPPA, 50CBS,and30PSP[21–24].”
Katz, S. (1963) · JAMA · doi:10.1001/jama.1963.03060120024016 · Cited by 2,421 · cited 1×
“…severity was assessed with the FTLD modified Clinical Dementia Rating (FTLD-modified CDR) sum of boxes scale [38], while the level of functional independence was assessed with the Basic Activities of Daily Living (BADL) [39] and the Instrumental Activities of Daily Living (IADL) questionnaires [40].”
Reactive Astrocytes: Production, Function, and Therapeutic Potential
Liddelow, S. A., & Barres, B. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.006 · Cited by 2,336
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · cited 1×
“In this context, increased GFAP levels have been reported in AD [17–19, 73 An interesting finding was the correlation between SAI and GFAP levels in AD subjects.”
Self-citationCriteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Self-citationTHE TOKEN TEST: A SENSITIVE TEST TO DETECT RECEPTIVE DISTURBANCES IN APHASICS
DE RENZI, E., & VIGNOLO, L. A. (1962) · Brain · doi:10.1093/brain/85.4.665 · Cited by 1,862 · cited 1×
“…battery which included the Mini-Mental State Examination (MMSE) [31], the Short Story Recall Test [32], the Rey Complex Figure (copy and recall) [33], phonemic and semantic fluencies [34], the Token Test [35], the Clock-Drawing Test [36], and Trail-Making Test (part A and part B) [37].”
Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationBang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144 · cited 1×
“…which is associated with early behavioral and executive deficits, the agrammatic variant of primary progressive aphasia (avPPA), with progressive deficits in speech, grammar and word output, and the semantic variant of PPA (svPPA), which is a progressive disorder of semantic knowledge and naming [1].”
Interaction between intracortical inhibition and facilitation in human motor cortex.
Ziemann, U., Rothwell, J. C., & Ridding, M. C. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021734 · Cited by 1,140 · cited 1×
“ForSICI and ICF, the conditioning stimulus (CS) was adjusted at 70% of the RMT, employing multiple interstimulus intervals (ISIs), including 1, 2, 3 ms for SICI and 7, 10, 15 ms for ICF [47, 48].”
Trail making test: normative values from 287 normal adult controls
Giovagnoli, A. R., Del Pesce, M., Mascheroni, S., Simoncelli, M., Laiacona, M., & Capitani, E. (1996) · The Italian Journal of Neurological Sciences · doi:10.1007/bf01997792 · Cited by 1,111
Cairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110
Clock Drawing in Alzheimer's Disease: A Novel Measure of Dementia Severity
Sunderland, T., Hill, J. L., Mellow, A. M., Lawlor, B. A., Gundersheimer, J., Newhouse, P. A., & Grafman, J. H. (1989) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1989.tb02233.x · Cited by 1,029
Short latency inhibition of human hand motor cortex by somatosensory input from the hand
Tokimura, H., Di Lazzaro, V., Tokimura, Y., Oliviero, A., Profice, P., Insola, A., Mazzone, P., Tonali, P., & Rothwell, J. C. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.t01-1-00503.x · Cited by 770 · cited 1×
“:3) s) of electrical stimulation delivered to right median nerve at the wrist, using a bipolar electrode with the cathode positioned proximally, at an intensity suffi-cient to evoke a visible twitch of the thenar muscles [50].”
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Self-citationMini‐Mental State Examination: a normative study in Italian elderly population
Magni, E., Binetti, G., Bianchetti, A., Rozzini, R., & Trabucchi, M. (1996) · European Journal of Neurology · doi:10.1111/j.1468-1331.1996.tb00423.x · Cited by 726 · cited 1×
“Patients underwent a standardized neuropsychological battery which included the Mini-Mental State Examination (MMSE) [31], the Short Story Recall Test [32], the Rey Complex Figure (copy and recall) [33], phonemic and semantic fluencies [34], the Token Test [35], the Clock-Drawing Test [36], and…”
Self-citationRey-Osterrieth complex figure: normative values in an Italian population sample
Caffarra, P., Vezzadini, G., Dieci, F., Zonato, F., & Venneri, A. (2002) · Neurological Sciences · doi:10.1007/s100720200003 · Cited by 722
The overlap of amyotrophic lateral sclerosis and frontotemporal dementia
Lomen-Hoerth, C., Anderson, T., & Miller, B. (2002) · Neurology · doi:10.1212/wnl.59.7.1077 · Cited by 699 · cited 1×
“A significant percentage of patients have associated extrapyramidal symptoms, as in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) [2], and there is considerable clinical overlap with motor neuron disease [3].”
Human motor evoked responses to paired transcranial magnetic stimuli
Valls-Solé, J., Pascual-Leone, A., Wassermann, E. M., & Hallett, M. (1992) · Electroencephalography and Clinical Neurophysiology/Evoked Potentials Section · doi:10.1016/0168-5597(92)90048-g · Cited by 687 · cited 1×
“LICI was investigated by implementing two supra-threshold stimuli, with the CS adjusted at 130% of the RMT, employing ISIs of 50, 100 and 150 ms [49].”
Ziemann, U., Reis, J., Schwenkreis, P., Rosanova, M., Strafella, A., Badawy, R., & Müller-Dahlhaus, F. (2015) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.08.028 · Cited by 681 · cited 2×
“We observed that elevated serum GFAP levels were related to a greater impairment in LICI, which is considered to reflect short-lasting postsynaptic inhibition mediated through the GABA B receptor at the level of local interneurons [28, 29].”
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. (2008) · Brain · doi:10.1093/brain/awn234 · Cited by 442 · cited 1×
“Disease severity was assessed with the FTLD modified Clinical Dementia Rating (FTLD-modified CDR) sum of boxes scale [38], while the level of functional independence was assessed with the Basic Activities of Daily Living (BADL) [39] and the Instrumental Activities of Daily Living (IADL)…”
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
Rohrer, J. D., Woollacott, I. O. C., Dick, K. M., Brotherhood, E., Gordon, E., Fellows, A., Toombs, J., Druyeh, R., Cardoso, M. J., Ourselin, S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003154 · Cited by 432
Self-citationDi Lazzaro, V., Oliviero, A., Profice, P., Pennisi, M. A., Di Giovanni, S., Zito, G., Tonali, P., & Rothwell, J. C. (2000) · Experimental Brain Research · doi:10.1007/s002210000543 · Cited by 381 · cited 1×
“…reflect the activity of several neurotransmitters, including GABA A by short interval intracortical inhibition (SICI), glutamate by intracortical facilitation (ICF), GABA B by long interval intracortical inhibition (LICI), and acetylcholine by short latency afferent inhibition (SAI) [28–30].”
Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A. M., Neugebauer, H., von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180325 · Cited by 345
Hodges, J. R., Patterson, K., Ward, R., Garrard, P., Bak, T., Perry, R., & Gregory, C. (1999) · Neuropsychology · doi:10.1037/0894-4105.13.1.31 · Cited by 335 · cited 1×
“As expected, we did not observe significant associations with memory and visuospatial abilities, considering that they are not compromised until later in the disease [58].”
Mackenzie, I. R. A., Baborie, A., Pickering-Brown, S., Plessis, D. D., Jaros, E., Perry, R. H., Neary, D., Snowden, J. S., & Mann, D. M. A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0138-9 · Cited by 323 · cited 1×
“These clinical phenotypes share common underlying molecular and pathological substrates, and in most cases, inclusions of microtubule-associated protein tau or TAR DNA-binding protein 43 (TDP-43) represent the pathological hallmarks of the disease [4, 5].”
Neurofilament light chain: a biomarker for genetic frontotemporal dementia
Meeter, L. H., Dopper, E. G., Jiskoot, L. C., Sanchez‐Valle, R., Graff, C., Benussi, L., Ghidoni, R., Pijnenburg, Y. A., Borroni, B., Galimberti, D., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.325 · Cited by 263
Self-citationDi Lazzaro, V., Pilato, F., Dileone, M., Profice, P., Ranieri, F., Ricci, V., Bria, P., Tonali, P. A., & Ziemann, U. (2007) · Clinical Neurophysiology · doi:10.1016/j.clinph.2007.07.005 · Cited by 240
Di Lazzaro, V., Oliviero, A., Saturno, E., Dileone, M., Pilato, F., Nardone, R., Ranieri, F., Musumeci, G., Fiorilla, T., & Tonali, P. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2004.061747 · Cited by 236
Sun, Y., Wu, S., Bu, G., Onifade, M. K., Patel, S. N., LaDu, M. J., Fagan, A. M., & Holtzman, D. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03261.1998 · Cited by 213
Papa, L., Silvestri, S., Brophy, G. M., Giordano, P., Falk, J. L., Braga, C. F., Tan, C. N., Ameli, N. J., Demery, J. A., Dixit, N. K., et al. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2013.3245 · Cited by 205 · cited 1×
“Increased GFAP levels have been observed also after stroke [71] and brain injury [72], but also in neurodegenerative processes with astrogliosis.”
Dissociated effects of diazepam and lorazepam on short‐latency afferent inhibition
Di Lazzaro, V., Pilato, F., Dileone, M., Tonali, P. A., & Ziemann, U. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.092155 · Cited by 201 · cited 1×
“…impairment (GFAP driven or associated) could also link the two findings (increased GFAP and SAI) as SAI is thought to be modulated by GABA activity [77–79] in a distinct way from SICI and LICI, through reciprocally connected subtypes of GABA inhibitory interneurons with convergent projections on…”
Glia as drivers of abnormal neuronal activity
Robel, S., & Sontheimer, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4184 · Cited by 198 · cited 1×
“This is in line with the existence of a dynamic GABAergic-astrocyte communication, with GFAP being a major component of the astrocytic cytoskeleton [67, 68], in line with previous studies showing that LICI predicted functional decline in FTD patients [65].”
Hutchinson, A. D., & Mathias, J. L. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100669 · Cited by 187
Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321954 · Cited by 182
Self-citationDvorak, F., Haberer, I., Sitzer, M., & Foerch, C. (2009) · Cerebrovascular Diseases · doi:10.1159/000172632 · Cited by 163 · cited 1×
“Increased GFAP levels have been observed also after stroke [71] and brain injury [72], but also in neurodegenerative processes with astrogliosis.”
Ishiki, A., Kamada, M., Kawamura, Y., Terao, C., Shimoda, F., Tomita, N., Arai, H., & Furukawa, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13399 · Cited by 156
Diagnostic and prognostic value of serum NfL and p-Tau181in frontotemporal lobar degeneration
Benussi, A., Karikari, T. K., Ashton, N., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Simrén, J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323487 · Cited by 155
Self-citationCSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia
Abu-Rumeileh, S., Steinacker, P., Polischi, B., Mammana, A., Bartoletti-Stella, A., Oeckl, P., Baiardi, S., Zenesini, C., Huss, A., Cortelli, P., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0562-4 · Cited by 154
Holmberg, B., Rosengren, L., Karlsson, J., & Johnels, B. (1998) · Movement Disorders · doi:10.1002/mds.870130116 · Cited by 142
Vågberg, M., Norgren, N., Dring, A., Lindqvist, T., Birgander, R., Zetterberg, H., & Svenningsson, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135886 · Cited by 141
Self-citationOeckl, P., Weydt, P., Steinacker, P., Anderl-Straub, S., Nordin, F., Volk, A. E., Diehl-Schmid, J., Andersen, P. M., Kornhuber, J., Danek, A., et al. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318868 · Cited by 139
Parkinsonism, movement disorders and genetics in frontotemporal dementia
Baizabal-Carvallo, J. F., & Jankovic, J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.14 · Cited by 121 · cited 1×
“A significant percentage of patients have associated extrapyramidal symptoms, as in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) [2], and there is considerable clinical overlap with motor neuron disease [3].”
GABAergic‐astrocyte signaling: A refinement of inhibitory brain networks
Mederos, S., & Perea, G. (2019) · Glia · doi:10.1002/glia.23644 · Cited by 115
Constantinescu, R., Rosengren, L., Johnels, B., Zetterberg, H., & Holmberg, B. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.07.007 · Cited by 114
Self-citationAlberici, A., Geroldi, C., Cotelli, M., Adorni, A., Calabria, M., Rossi, G., Borroni, B., Padovani, A., Zanetti, O. O., & Kertesz, A. (2007) · Neurological Sciences · doi:10.1007/s10072-007-0791-3 · Cited by 108
Self-citationDi Lorenzo, F., Ponzo, V., Bonnì, S., Motta, C., Negrão Serra, P. C., Bozzali, M., Caltagirone, C., Martorana, A., & Koch, G. (2016) · Annals of Neurology · doi:10.1002/ana.24695 · Cited by 108
Arias, C., Zepeda, A., Hernández‐Ortega, K., Leal‐Galicia, P., Lojero, C., & Camacho‐Arroyo, I. (2008) · Hormones and Behavior · doi:10.1016/j.yhbeh.2008.10.016 · Cited by 94 · cited 1×
“Animal models have shown that GFAP expression is highly dependent on sex hormones, and differences have been detected between males and females in the hippocampus, striatum, and cerebellum [56].”
Benussi, A., Grassi, M., Palluzzi, F., Koch, G., Di Lazzaro, V., Nardone, R., Cantoni, V., Dell'Era, V., Premi, E., Martorana, A., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25677 · Cited by 91 · cited 1×
“…proposed neurophysiological markers, measuring FTLD-related neurotransmitter deficits non-invasively by transcranial magnetic stimulation (TMS) [8], a giant step forward toward potentially useful biomarkers has been made with the new ultrasensitive Single molecule array (Simoa) approach and…”
Self-citationToward a glutamate hypothesis of frontotemporal dementia
Benussi, A., Alberici, A., Buratti, E., Ghidoni, R., Gardoni, F., Di Luca, M., Padovani, A., & Borroni, B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00304 · Cited by 90
Self-citationTranscranial magnetic stimulation predicts cognitive decline in patients with Alzheimer’s disease
Motta, C., Di Lorenzo, F., Ponzo, V., Pellicciari, M. C., Bonnì, S., Picazio, S., Mercuri, N. B., Caltagirone, C., Martorana, A., & Koch, G. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317879 · Cited by 89 · cited 1×
“It could be speculated that LICI, reflecting GABA B impairment linked to GFAP, could be used as neurophysiological biomarker also for FTLD, in analogy with what has been observed in AD, in which different TMS measures can be used to predict functional decline [69, 70].”
Ithapu, V., Singh, V., Lindner, C., Austin, B. P., Hinrichs, C., Carlsson, C. M., Bendlin, B. B., & Johnson, S. C. (2014) · Human Brain Mapping · doi:10.1002/hbm.22472 · Cited by 85
Alle, H., Heidegger, T., Kriváneková, L., & Ziemann, U. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.179820 · Cited by 72 · cited 1×
“…could also link the two findings (increased GFAP and SAI) as SAI is thought to be modulated by GABA activity [77–79] in a distinct way from SICI and LICI, through reciprocally connected subtypes of GABA inhibitory interneurons with convergent projections on corticospinal neurons [80, 81].”
Padovani, A., Benussi, A., Cantoni, V., Dell’Era, V., Cotelli, M. S., Caratozzolo, S., Turrone, R., Rozzini, L., Alberici, A., Altomare, D., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180293 · Cited by 70 · cited 1×
“We also observed an association between serum GFAP concentration and indirect measures of GABAergic neurotransmission, which have been demonstrated to be impaired in FTLD [59–64], and reflect disease severity and progression [65, 66].”
Self-citationConstantinescu, R., Zetterberg, H., Holmberg, B., & Rosengren, L. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.05.001 · Cited by 69
Self-citationPlasma tau is increased in frontotemporal dementia
Foiani, M. S., Woollacott, I. O., Heller, C., Bocchetta, M., Heslegrave, A., Dick, K. M., Russell, L. L., Marshall, C. R., Mead, S., Schott, J. M., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317260 · Cited by 64 · cited 1×
“It has been clearly proven that concentrations of blood neurofilament light (NfL), a marker of axonal damage, are increased in FTLD and may be related to parameters of disease severity and prognosis [9–11].”
Self-citationYoung-Bernier, M., Tanguay, A. F. N., Davidson, P. S. R., & Tremblay, F. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00182 · Cited by 63
Clinical and biomarker changes in presymptomatic genetic frontotemporal dementia
Benussi, A., Gazzina, S., Premi, E., Cosseddu, M., Archetti, S., Dell’Era, V., Cantoni, V., Cotelli, M. S., Alberici, A., Micheli, A., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.12.018 · Cited by 62 · cited 1×
“A TMS figure-of-eight coil (each loop diameter 70 mm – D70 2 coil) connected to a monophasic Magstim Bistim 2 system (Magstim Company, Oxford, UK) was employed for all TMS paradigms, as previously reported [46].”
Self-citationAlegret, M., Muñoz, N., Roberto, N., Rentz, D. M., Valero, S., Gil, S., Marquié, M., Hernández, I., Riveros, C., Sanabria, A., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00594-6 · Cited by 55
Martorana, A., Di Lorenzo, F., Manenti, G., Semprini, R., & Koch, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00254 · Cited by 53
Benussi, A., Alberici, A., Ferrari, C., Cantoni, V., Dell’Era, V., Turrone, R., Cotelli, M. S., Binetti, G., Paghera, B., Koch, G., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0423-6 · Cited by 50
Self-citationTMS for staging and predicting functional decline in frontotemporal dementia
Benussi, A., Dell’Era, V., Cantoni, V., Cotelli, M. S., Cosseddu, M., Spallazzi, M., Micheli, A., Turrone, R., Alberici, A., & Borroni, B. (2019) · Brain stimulation · doi:10.1016/j.brs.2019.11.009 · Cited by 50 · cited 2×
“This is in line with the existence of a dynamic GABAergic-astrocyte communication, with GFAP being a major component of the astrocytic cytoskeleton [67, 68], in line with previous studies showing that LICI predicted functional decline in FTD patients [65].”
Self-citationDiscrimination of atypical parkinsonisms with transcranial magnetic stimulation
Benussi, A., Dell'Era, V., Cantoni, V., Ferrari, C., Caratozzolo, S., Rozzini, L., Alberici, A., Padovani, A., & Borroni, B. (2018) · Brain Stimulation · doi:10.1016/j.brs.2017.11.013 · Cited by 49
Self-citationDifferential pattern of brain‐specific CSF proteins tau and amyloid‐beta in Parkinsonian syndromes
Süssmuth, S. D., Uttner, I., Landwehrmeyer, B., Pinkhardt, E. H., Brettschneider, J., Petzold, A., Kramer, B., Schulz, J. B., Palm, C., Otto, M., et al. (2010) · Movement Disorders · doi:10.1002/mds.22895 · Cited by 47 · cited 1×
“On the contrary, several reports have shown that PSP patients have only slightly, non-significantly increased CSF levels of GFAP compared to healthy controls [52–55].”
Cosseddu, M., Benussi, A., Gazzina, S., Alberici, A., Dell'Era, V., Manes, M., Cristillo, V., Borroni, B., & Padovani, A. (2020) · European Journal of Neurology · doi:10.1111/ene.14071 · Cited by 47 · cited 1×
“Furthermore, neuropsychiatric and behavioral disturbances were evaluated with the Frontal Behavior Inventory (FBI) [41, 42].”
Self-citationSudre, C. H., Bocchetta, M., Heller, C., Convery, R., Neason, M., Moore, K. M., Cash, D. M., Thomas, D. L., Woollacott, I. O. C., Foiani, M., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.102077 · Cited by 47
Self-citationBorroni, B., Benussi, A., Premi, E., Alberici, A., Marcello, E., Gardoni, F., Di Luca, M., & Padovani, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170584 · Cited by 36 · cited 1×
“A multitude of markers of disease severity have been recognized in the last decade, ranging from neuroimaging with magnetic resonance imaging (MRI) or positron emission tomography (PET), to cerebrospinal fluid (CSF) biomarkers (for a review, see [6, 7]).”
Self-citationFostinelli, S., Ciani, M., Zanardini, R., Zanetti, O. O., Binetti, G. G., Ghidoni, R., & Benussi, L. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170661 · Cited by 36
Self-citationWhite matter hyperintensities characterize monogenic frontotemporal dementia with granulin mutations
Paternicò, D., Premi, E., Gazzina, S., Cosseddu, M., Alberici, A., Archetti, S., Cotelli, M. S., Micheli, A., Turla, M., Gasparotti, R., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.011 · Cited by 35 · cited 1×
“A per-subject summary measure of total white matter hyperintensities volume burden was automatically calculated on the probability map outputs, adjusting for intracranial volume to account for the differences in brain sizes [45].”
Self-citationNeurophysiological Correlates of Positive and Negative Symptoms in Frontotemporal Dementia
Benussi, A., Dell’Era, V., Cantoni, V., Cotelli, M. S., Cosseddu, M., Spallazzi, M., Alberici, A., Padovani, A., & Borroni, B. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190986 · Cited by 33 · cited 1×
“We also observed an association between serum GFAP concentration and indirect measures of GABAergic neurotransmission, which have been demonstrated to be impaired in FTLD [59–64], and reflect disease severity and progression [65, 66].”
Self-citationCerebrospinal Fluid Tau Levels Predict Prognosis in Non-Inherited Frontotemporal Dementia
Borroni, B., Benussi, A., Cosseddu, M., Archetti, S., & Padovani, A. (2014) · Neurodegenerative Diseases · doi:10.1159/000353280 · Cited by 28 · cited 1×
“Inall cases,thediagnosiswassupportedbybrainstructural imaging,whileCSFconcentrationsofT-tau,P-tau 181 , and A (cid:2) 1 – 42 were measured in a subset of cases (45.0%), to rule out AD, as previously reported [26].”
InfluentialSelf-citationGazzina, S., Benussi, A., Premi, E., Paternicò, D., Cristillo, V., Dell’Era, V., Cosseddu, M., Archetti, S., Alberici, A., Gasparotti, R., et al. (2017) · Brain Topography · doi:10.1007/s10548-017-0612-9 · Cited by 28 · cited 1×
“We also observed an association between serum GFAP concentration and indirect measures of GABAergic neurotransmission, which have been demonstrated to be impaired in FTLD [59–64], and reflect disease severity and progression [65, 66].”
Self-citationPadovani, A., Benussi, A., Cotelli, M. S., Ferrari, C., Cantoni, V., Dell’Era, V., Turrone, R., Paghera, B., & Borroni, B. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0555-3 · Cited by 27
Self-citationLooking for measures of disease severity in the frontotemporal dementia continuum
Premi, E., Gualeni, V., Costa, P., Cosseddu, M., Gasparotti, R., Padovani, A., & Borroni, B. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160178 · Cited by 26 · cited 1×
“Grey matter was assessed by voxel based morphometry (VBM) analysis [43] Moreover, we considered white matter hyperintensities burden, computed on T1-weighted and T2 FLAIR images using the Wisconsin White Matter Hyperintensities Segmentation Toolbox version 1.3 [44].”
InfluentialSelf-citationMarelli, C., Hourregue, C., Gutierrez, L.-A., Paquet, C., Menjot de Champfleur, N., De Verbizier, D., Jacob, M., Dubois, J., Maleska, A. M., Hirtz, C., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190378 · Cited by 21 · cited 1×
“…in most FTLD subgroups, including both the behavioral and language variants of FTD, CBS, but not in PSP. Similarly, previous reports have shown that GFAP levels are increased in CSF and plasma of sporadic FTD patients [16, 17, 19, 51] and in plasma of symptomatic granulin-associated FTD [15, 20].”
Emergence of neurophysiological biomarkers of Alzheimer disease
Lazzaro, V. D. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318867 · Cited by 8 · cited 1×
“It could be speculated that LICI, reflecting GABA B impairment linked to GFAP, could be used as neurophysiological biomarker also for FTLD, in analogy with what has been observed in AD, in which different TMS measures can be used to predict functional decline [69, 70].”
Deun, K. V., Thorrez, L., van den Berg, R. A., Smilde, A. K., & Mechelen, I. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125334 · Cited by 5
Research works printed but not linked: 4
- Meeter LH, 2017, Nat Rev Neurol, 19, 109
- Abu-Rumeileh S, 2019, Alzheimers Res Ther, 12, 1
- Novelli G, 1970, Arch Psicol Neurol Psichiatr, 47, 278
- Novelli G, 1986, Arch Psicol Neurol Psichiatr, 47, 477
Cited by
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
“74,79,80 Concentrations were also elevated in Lewy body dementia compared with both controls and people with Parkinson’s disease.”
Self-citationBlood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638
Self-citationGFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309
“7, 154) 164 (125, 223) Benussi, 2020 [37] Italy HC/AD 61 (20.”
Baiardi, S., Quadalti, C., Mammana, A., Dellavalle, S., Zenesini, C., Sambati, L., Pantieri, R., Polischi, B., Romano, L., Suffritti, M., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01093-6 · Cited by 193
“Our FTD cohort included both GRN carriers (10% of cases) and patients with severe disease (7% with CRD-FTLD ≥ 3), two conditions known to be associated with increased biomarker levels [49, 51].”
Background
Metadata
- Authors
- Benussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., Fostinelli, S., Giunta, M., Gasparotti, R., Zetterberg, H., Blennow, K., & Borroni, B.
- Affiliations
- University of Brescia (IT)
- King's College London (GB)
- University of Gothenburg (SE)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Ljubljana University Medical Centre (SI)
- Corresponding author
- Borroni, Barbara
- ORCID
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2020-08-14
- Volume
- 77
- Issue
- 3
- Pages
- 1129-1141
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W3049719602
- Cited by
- 113
- References
- 80
- Citations by year
- 2026: 11 · 2025: 24 · 2024: 22 · 2023: 21 · 2022: 16 · 2021: 17 · 2020: 1
- FWCI
- 9.97
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Funders
- Alzheimer's Drug Discovery Foundation (2016862, FO2017-0243, 201809, 2017-00915, #ALFGBG-715986, 201809–2016862, JPND2019-466-236, 201809-2016615, #RDAPB‐201809‐2016615, AF-742881)
- EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
- European Commission (JPND2019‐466‐236)
- Ministero della Salute (2018-)
- Hjärnfonden (FO2017‑0243, FO2017, ALFGBG-715986, JPND2019-466-236)
- Vetenskapsrådet (2017-00915, (#ALFGBG-715986, 681712, 2018-, JPND2019-466-236, FO2017-0243, 2018-02532)
- UK Dementia Research Institute (#2017-00915)
- H2020 European Research Council (681712)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- glial fibrillary acidic protein, serum biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Biomarkers, Frontotemporal Lobar Degeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.